Neuroinflammation has been involved in neurodegenerative diseases and acute brain injury such as stroke. monocytes chemotactic protein -1-induced protein -1 (Mcpip1) is a multifunctional protein action is known to have pro-apoptotic or anti-apoptotic depending on the nature of the experimental arrangement. However, its role in brain damage after asphyxia in the developing brain has not been studied. Therefore, we explored the role Mcpip1 on brain injury after hypoxia-ischemia in neonatal rats.

At postnatal day 7, Mcpip1-deficient and wild-type mice carotid artery ligation and exposure to hypoxia (8% oxygen). After a hypoxic-ischemic insult, we determine the time-course of cell death of apoptosis and expression levels of genes that encode proinflammatory factors. Mcpip1 impact on long-term brain damage rated one week after hypoxia-ischemia by cresyl violet staining.

We found caspase- 3 significantly increased activity in the ipsilateral brain tissue within 12-24 hours after hypoxia-ischemia. There is a marked increase in levels of mRNA transcripts that encode Mcpip1, TNF, and CCL2 in the ipsilateral brain tissue 6-48 hours after hypoxia-ischemia. We found caspase- hypoxia-ischemia-induced 3 and the activity levels of proinflammatory genes are inactivated in Mcpip1-KO mice compared to wild-type mice.

Histological assessment revealed that hypoxia-ischemia-induced brain tissue loss was significantly attenuated in the hippocampus of Mcpip1-KO mice compared to wild-type mice (9.0 ± 5.6% vs 3 3 0.9 ± 11.0%, P <0.05). Our data show that Mcpip1 contributes to acute and delayed brain damage, in part, through the regulation of neuroinflammation after hypoxic-ischemic insult in the developing rat brain.

Monocyte chemotactic protein-1-induced protein 1 contributes to neuronal injury following hypoxic-ischemia in the neonatal mouse brain
Monocyte chemotactic protein-1-induced protein 1 contributes to neuronal injury following hypoxic-ischemia in the neonatal mouse brain

MCP-1 priming Enhanced Mesenchymal stromal cells Therapeutic Effect on Contact Hypersensitivity by Enabling COX2-PGE2 / STAT3 Pathway mesenchymal stromal

cells (MSC) has become a promising treatment for inflammation-related diseases, and the efficacy of their therapy mainly depends on the crosstalk between the MSC and inflammation. However, methods to improve the efficiency of immunosuppressive of MSC in different diseases still need to be developed. In this study, we investigated whether preconditioning MSC inflammatory cytokines associated with the disease can improve their immunosuppressive properties and increasing the success of therapy.

In a mouse model of contact hypersensitivity (CHS), an inflammatory profile screening revealed that among all the cytokines tested, monocytes chemotactic protein -1 (MCP- 1) exhibited the lowest level increased significantly in the local microenvironment. As expected, MSC asphalt with MCP-1 (P-MSCs) exhibited an enhanced ability to downregulate the secretion of proinflammatory cytokines, induce regulatory T cells, inhibiting T cell proliferation, and the polarization of M2-type macrophages.

In vivo experiments showed that P-MSCs alleviated ear swelling and local production of proinflammatory cytokines is more effective than MSC controls. Mechanically, MCP-1 can significantly activate signal transducer and activator of transcription 3 (STAT 3 ) signaling pathway and induces the expression of cyclooxygenase-2 (COX2) and prostaglandin E2 (PGE2) in the MSC. STAT 3 inhibitor reversed MCP-1-mediated increase their immunosuppressive capabilities.

Dimethylglyoxime disodium salt

DD1221 100g
EUR 76.7

Fluorescein, disodium salt

FB0203 100g
EUR 76.7

cGAMP disodium salt

2435-100
EUR 235.2

NADH, disodium salt

2735-1000
EUR 202.8

NADH, disodium salt

2735-500
EUR 170.4

NADH, disodium salt

2735-5000
EUR 652.8

NADP, disodium salt

2736-100
EUR 183.6

NADP, disodium salt

2736-1000
EUR 940.8

NADP, disodium salt

2736-500
EUR 548.4

NBQX disodium salt

2759-25
EUR 770.4

NBQX disodium salt

2759-5
EUR 248.4

BCA disodium salt

2810-100G
EUR 1038

BCA disodium salt

2810-1G
EUR 144

BCA disodium salt

2810-500G
EUR 3126

BCA disodium salt

2810-5G
EUR 261.6

Carbenicillin, Disodium Salt

A2511-5.1 10 mM (in 1mL DMSO)
EUR 129.6
Description: Carbenicillin inhibits the cell-wall synthesis (peptidoglycan cross-linking) by inactivating transpeptidase on the inner surface of the bacterial cell membrane.Carbenicillin is a white to slightly yellow, hygroscopic powder soluble in water and in alcohol.

Carbenicillin, Disodium Salt

A2511-50 50 mg
EUR 157.2
Description: Carbenicillin inhibits the cell-wall synthesis (peptidoglycan cross-linking) by inactivating transpeptidase on the inner surface of the bacterial cell membrane.Carbenicillin is a white to slightly yellow, hygroscopic powder soluble in water and in alcohol.

BCIP disodium salt

BB1171 500mg
EUR 279.24

ATP disodium salt

B3304-5.1 10 mM (in 1mL H2O)
EUR 129.6
Description: ATP Disodium salt is a P2 purinoceptor agonist.

ATP disodium salt

B3304-50 50 mg
EUR 153.6
Description: ATP Disodium salt is a P2 purinoceptor agonist.

ATP disodium salt

B3304-S Evaluation Sample
EUR 97.2
Description: ATP Disodium salt is a P2 purinoceptor agonist.

Phosphoramidon Disodium Salt

B4790-25 25 mg
EUR 588
Description: Phosphoramidon Disodium Salt is a potent inhibitor of metalloproteinase [1]. Metalloproteinase is an enzyme whose catalytic mechanism involves a metal. Most metalloproteases require zinc and some require cobalt.

Phosphoramidon Disodium Salt

B4790-5 5 mg
EUR 226.8
Description: Phosphoramidon Disodium Salt is a potent inhibitor of metalloproteinase [1]. Metalloproteinase is an enzyme whose catalytic mechanism involves a metal. Most metalloproteases require zinc and some require cobalt.

DNQX disodium salt

B5288-100 100 mg
EUR 334.8

DNQX disodium salt

B5288-25 25 mg
EUR 153.6

DNQX disodium salt

B5288-50 50 mg
EUR 223.2

Hypoxanthine Disodium Salt

B1185-1G
EUR 130.8

Hypoxanthine Disodium Salt

B1185-5G
EUR 288

NBQX disodium salt

B6566-10 10 mg
EUR 266.4

NBQX disodium salt

B6566-25 25 mg
EUR 466.8

NBQX disodium salt

B6566-5 5 mg
EUR 166.8

NBQX disodium salt

B6566-50 50 mg
EUR 819.6

CNQX disodium salt

B6567-1 1 mg
EUR 160.8

CNQX disodium salt

B6567-10 10 mg
EUR 258

CNQX disodium salt

B6567-50 50 mg
EUR 895.2

UDP disodium salt

B7278-5.1 10 mM (in 1mL DMSO)
EUR 129.6

UDP disodium salt

B7278-50 50 mg
EUR 150

Phosphocreatine disodium salt

B7648-25 25 mg
EUR 235.2

cGAMP disodium salt

GL2101-100UG 100 ug
EUR 192

cGAMP disodium salt

GL2101-500UG 500 ug
EUR 398.4

Etidronate disodium salt

GP3560-1G 1 g
EUR 208.8

Lobenzarit disodium salt

GP3753-100MG 100 mg
EUR 274.8

Carbenicillin disodium salt

GA1299-10G 10 g
EUR 274.8

Carbenicillin disodium salt

GA1299-1G 1 g
EUR 103.2

Carbenicillin disodium salt

GA1299-250MG 250 mg
EUR 70.8

Carbenicillin disodium salt

GA1299-25G 25 g
EUR 409.2

Carbenicillin disodium salt

GA1299-5G 5 g
EUR 189.6

Ticarcillin disodium salt

GA1874-100MG 100 mg
EUR 60

Ticarcillin disodium salt

GA1874-1G 1 g
EUR 132

Ticarcillin disodium salt

GA1874-500MG 500 mg
EUR 93.6

Cefotetan disodium salt

GA5476-100MG 100 mg
EUR 103.2

Cefotetan disodium salt

GA5476-1G 1 g
EUR 217.2

Phosphomycin disodium salt

GA7173-1G 1 g
EUR 84

Phosphomycin disodium salt

GA7173-25G 25 g
EUR 346.8

Phosphomycin disodium salt

GA7173-5G 5 g
EUR 160.8

ADA disodium salt

GB0256-100G 100 g
EUR 132

ADA disodium salt

GB0256-500G 500 g
EUR 409.2

PIPES disodium salt

GB1799-100G 100 g
EUR 132

PIPES disodium salt

GB1799-250G 250 g
EUR 217.2

PIPES disodium salt

GB1799-25G 25 g
EUR 84

PIPES disodium salt

GB1799-500G 500 g
EUR 370.8

POPSO disodium salt

GB6170-100G 100 g
EUR 322.8

POPSO disodium salt

GB6170-25G 25 g
EUR 151.2

ATP (disodium salt)

HY-B0345A 10mM/1mL
EUR 135.6

NADH (disodium salt)

HY-F0001 10mM/1mL
EUR 135.6

NADP (disodium salt)

HY-F0002A 500mg
EUR 325.2

Balsalazide disodium salt

GP7647-1G 1 g
EUR 132

Methoxatin (disodium salt)

HY-100196A 10mM/1mL
EUR 223.2

POPSO, disodium salt

PB4959 25g
EUR 92.36

EDTA, Disodium Salt, Dihydrate

CH032 500 g
EUR 195.6

EDTA, Disodium Salt, Dihydrate

CH033 1.0 kg
EUR 234

EDTA, Disodium Salt, Dihydrate

CH034 2.5 kg
EUR 400.8

ADA buffer, disodium salt

AB0005 25g
EUR 79.84

CL 316243 disodium salt

B6766-1 1 mg
EUR 130.8
Description: EC50: (3.0±0.3) X 10-8 M for ?3 adrenoceptor [1].Benzodioxole-containing phenethanolamine CL-316,243 is a murine-selective ?3 adrenoceptor agonist which can correct obesity and elevated blood glucose in diabetic rodents.

CL 316243 disodium salt

B6766-10 10 mg
EUR 351.6
Description: EC50: (3.0±0.3) X 10-8 M for ?3 adrenoceptor [1].Benzodioxole-containing phenethanolamine CL-316,243 is a murine-selective ?3 adrenoceptor agonist which can correct obesity and elevated blood glucose in diabetic rodents.

CL 316243 disodium salt

B6766-5 5 mg
EUR 247.2
Description: EC50: (3.0±0.3) X 10-8 M for ?3 adrenoceptor [1].Benzodioxole-containing phenethanolamine CL-316,243 is a murine-selective ?3 adrenoceptor agonist which can correct obesity and elevated blood glucose in diabetic rodents.

Pamoic acid disodium salt

B7638-10 10 mg
EUR 576

Pamoic acid disodium salt

B7638-50 50 mg
EUR 2233.2

MUP, disodium salt, trihydrate

M0740 1g
EUR 112.2

EDTA, disodium salt, dihydrate

EB0185 500g
EUR 84.01

Pamoic acid disodium salt

GK6564-100G 100 g
EUR 103.2

Pamoic acid disodium salt

GK6564-250G 250 g
EUR 170.4

Pamoic acid disodium salt

GK6564-25G 25 g
EUR 64.8

Sulfobromophthalein disodium salt hydrate

GK6995-25G 25 g
EUR 294

Sulfobromophthalein disodium salt hydrate

GK6995-5G 5 g
EUR 132

Clodronate disodium salt hydrate

GP6103-1G 1 g
EUR 103.2

UDP-GlcNAc Disodium Salt

HY-112174 5mg
EUR 198

Bathocuproinedisulfonic acid disodium salt

GT0734-100MG 100 mg
EUR 60

Bathocuproinedisulfonic acid disodium salt

GT0734-1G 1 g
EUR 132

Bathocuproinedisulfonic acid disodium salt

GT0734-250MG 250 mg
EUR 74.4

Bathocuproinedisulfonic acid disodium salt

GT0734-500MG 500 mg
EUR 96

EDTA disodium salt dihydrate

GE3023-100G 100 g
EUR 48

EDTA disodium salt dihydrate

GE3023-1KG 1 kg
EUR 84

EDTA disodium salt dihydrate

GE3023-250G 250 g
EUR 55.2

EDTA disodium salt dihydrate

GE3023-500G 500 g
EUR 64.8

EDTA disodium salt dihydrate

GE3023-5KG 5 kg
EUR 180

MUP, disodium salt [4-Methylumbelliferyl phosphate, disodium salt] *CAS 22919-26-2*

11610 25 mg
EUR 138

MUP, disodium salt [4-Methylumbelliferyl phosphate, disodium salt] *CAS 22919-26-2*

11612 10 g
EUR 1077.6

Creatine phosphate, disodium salt, Tetrahydrate

CB0128 5g
EUR 85.06

DL-?-Hydroxyglutaric acid disodium salt

A3837-100 100 mg
EUR 223.2
Description: IC50: N/AD-?-Hydroxyglutaric acid, an ?-hydroxy acid formed from the hydrolysis of (R)-5-oxo-2-tetrahydrofurancarboxylic acid, is over-produced in the human neurometabolic disease D-?-hydroxyglutaric aciduria.

DL-?-Hydroxyglutaric acid disodium salt

A3837-25 25 mg
EUR 141.6
Description: IC50: N/AD-?-Hydroxyglutaric acid, an ?-hydroxy acid formed from the hydrolysis of (R)-5-oxo-2-tetrahydrofurancarboxylic acid, is over-produced in the human neurometabolic disease D-?-hydroxyglutaric aciduria.

DL-?-Hydroxyglutaric acid disodium salt

A3837-50 50 mg
EUR 184.8
Description: IC50: N/AD-?-Hydroxyglutaric acid, an ?-hydroxy acid formed from the hydrolysis of (R)-5-oxo-2-tetrahydrofurancarboxylic acid, is over-produced in the human neurometabolic disease D-?-hydroxyglutaric aciduria.

EDTA disodium and monocalcium salt

EK014P2 500g
EUR 115.33

Guanosine 5'-triphosphate disodium salt

20-abx180774
  • EUR 360.00
  • EUR 678.00
  • 1 g
  • 5 g

Chromotropic Acid Disodium Salt Dihydrate

20-abx186412
  • EUR 393.60
  • EUR 276.00
  • 100 g
  • 25 g

BCA (Bicinchoninic acid), disodium salt

BB0260 5g
EUR 185.28

L-?-Hydroxyglutaric Acid Disodium Salt

B2812-25
EUR 418.8

L-?-Hydroxyglutaric Acid Disodium Salt

B2812-5
EUR 157.2

NADH disodium salt, trihydrate, reduced

NB0642 1g
EUR 98.63

EDTA copper(II) disodium salt

EB0434 250g
EUR 100.72

EDTA disodium and monomagnesium salt

EB0435 500g
EUR 133.08

EDTA zinc (II), disodium salt

EB6666 100g
EUR 77.75

Uridine-5'-diphosphate disodium salt

HY-W010832 100mg
EUR 129.6

5'-Guanylic acid (disodium salt)

HY-W010970 10mM/1mL
EUR 135.6

Uridine 5'-monophosphate disodium salt

HY-W013175 100mg
EUR 129.6

Bicinchoninic acid disodium salt hydrate

GK3616-10G 10 g
EUR 160.8

Bicinchoninic acid disodium salt hydrate

GK3616-1G 1 g
EUR 64.8

Bicinchoninic acid disodium salt hydrate

GK3616-25G 25 g
EUR 288

Bicinchoninic acid disodium salt hydrate

GK3616-5G 5 g
EUR 108

Succinic acid disodium salt, anhydrous

GK7702-100G 100 g
EUR 51.6

Succinic acid disodium salt, anhydrous

GK7702-1KG 1 kg
EUR 112.8

Succinic acid disodium salt, anhydrous

GK7702-250G 250 g
EUR 62.4

Succinic acid disodium salt, anhydrous

GK7702-500G 500 g
EUR 79.2

Succinic acid disodium salt, anhydrous

GK7702-5KG 5 kg
EUR 294

Dexamethasone 21-phosphate disodium salt

GL6086-1G 1 g
EUR 132

Dexamethasone 21-phosphate disodium salt

GL6086-5G 5 g
EUR 322.8

Xanthosine 5'-monophosphate disodium salt

GN2077-100MG 100 mg
EUR 274.8

Xanthosine 5'-monophosphate disodium salt

GN2077-25MG 25 mg
EUR 112.8

Adenosine 5'-monophosphate disodium salt

GN7778-10G 10 g
EUR 98.4

Adenosine 5'-monophosphate disodium salt

GN7778-1G 1 g
EUR 60

Adenosine 5'-monophosphate disodium salt

GN7778-25G 25 g
EUR 151.2

Adenosine 5'-monophosphate disodium salt

GN7778-5G 5 g
EUR 74.4

Ceftriaxone disodium salt hemi(heptahydrate)

GA6812-1G 1 g
EUR 74.4

Ceftriaxone disodium salt hemi(heptahydrate)

GA6812-25G 25 g
EUR 274.8

Ceftriaxone disodium salt hemi(heptahydrate)

GA6812-5G 5 g
EUR 112.8

4-Methylumbelliferyl phosphate disodium salt

GC5745-1G 1 g
EUR 199.2

4-Methylumbelliferyl phosphate disodium salt

GC5745-250MG 250 mg
EUR 90

Uridine 5'-diphosphate disodium salt

GC9934-100MG 100 mg
EUR 88.8

Uridine 5'-diphosphate disodium salt

GC9934-1G 1 g
EUR 313.2

Uridine 5'-diphosphate disodium salt

GC9934-250MG 250 mg
EUR 132

Collectively, our findings indicate that MCP-1 related CHS conditioning increases immunomodulatory effects of MSC and enhanced their therapeutic efficacy in CHS. Improving the effectiveness of immunosuppressive MSC by preconditioning inflammatory cytokines associated with a particular disease may provide new strategies for MSC-based therapy for inflammatory disease.